



October 22, 2008

Re: IMPORTANT SUPPLY INFORMATION
Antivenin (Micrurus fulvius) (Equine Origin)
North American Coral Snake Antivenin
LOT No 4030026 - EXTENSION OF EXPIRATION DATING

Dear Health Care Provider:

This is to provide you with some very important information regarding Antivenin (Micrurus fulvius) (Equine Origin) North American Coral Snake Antivenin.

Wyeth Pharmaceuticals, working closely with the US Food and Drug Administration (FDA), is extending the expiration date of one lot of Antivenin, Lot No. 4030026, for an additional 12 months. Wyeth Pharmaceuticals has stability data that indicate that product from Lot No. 4030026 continues to be within applicable release specifications. **As a result, product from this lot, which is labeled to expire on October 31, 2008, will now be deemed to expire on October 31, 2009. FDA has reviewed the stability data and approved the extended dating, which applies only to Lot 4030026.**

As you may know, Wyeth Pharmaceuticals no longer manufactures Antivenin, and there is currently no alternative FDA-approved supplier of this product. **Accordingly, it is imperative that you do not discard any product you have in your inventory of Lot 4030026 at the end of the labeled expiration dating of October 2008. Please continue to maintain this product in your inventory and keep it available for use until October 31, 2009.**

Wyeth is closely managing Antivenin (Micrurus fulvius) inventories and will supply product only to direct customers.

Antivenin (Micrurus fulvius) (Equine Origin) is indicated for the treatment of envenomation caused by the bites of Micrurus fulvius fulvius (eastern coral snake) and M. fulvius tenere (Texas coral snake). Please see accompanying full Prescribing Information for indications and usage, dosage and administration, and important safety information. Also, the product prescribing information can be accessed at www.wyeth.com.

If you have any questions, please call our Customer Service Department at 1-800-666-7248.

Sincerely,

Joseph S Camardo, MD
Senior Vice President
Global Medical Affairs
Wyeth Pharmaceuticals

cc: US FDA